FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
Go back to FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease| BARNES GROUP, Inc. (NYSE: B) | Delayed: 37.16 -0.35 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.51 | 52 Week High | $44.27 | |||
| Open | $36.82 | 52 Week Low | $30.07 | |||
| Day High | $37.26 | P/E | 28.37 | |||
| Day Low | $36.42 | EPS | $1.31 | |||
| Volume | 8,471,087 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 21.90 -0.04 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.94 | 52 Week High | $8.73 | |||
| Open | $21.33 | 52 Week Low | $2.86 | |||
| Day High | $21.94 | P/E | N/A | |||
| Day Low | $21.19 | EPS | $-3.82 | |||
| Volume | 416,643 | |||||
